All Stories

  1. Comment on Mavroudis et al. Post-Traumatic Epilepsy After Mild and Moderate Traumatic Brain Injury: A Narrative Review and Development of a Clinical Decision Tool. Reports 2025, 8, 193
  2. Impact of Statin Therapy on the Risk of Stroke Recurrence, Mortality, and Dementia After Ischemic Stroke (ISMARDD Study): A Comprehensive Meta-Analysis
  3. Neuroimaging and Genetic Markers of Cerebral Small Vessel Disease and Cognitive Outcomes: A Systematic Review and Meta-Analysis (NEUROGEN-SVD Study)
  4. Health Research and Education during and after the COVID-19 Pandemic: An Australian Clinician and Researcher Perspective
  5. Use of Interval Therapy with Benzodiazepines to Prevent Seizure Recurrence in Stressful Situations
  6. Management and attitudes toward patients with epilepsy in general practice: How far have we come in three decades?
  7. A decision tree to determine fitness to drive in epilepsy: Results of a pilot in two Australian states
  8. Diagnostic Coding: A Novel Approach to Quality Assurance in Private Practice
  9. Commentary on “High incidence of persistent sub-therapeutic levels of most common AEDs in children with epilepsy receiving polypharmacy”
  10. Reflection on stroke deaths and end-of-life stroke care
  11. Training and Expectations for the Expert Witness in Australia: Could Guidelines Work in the US?
  12. Can head trauma trigger adult-onset Rasmussen's encephalitis?
  13. Medical certificates attesting fitness to drive
  14. Legal imperatives in treating severe stroke
  15. Fitness to drive — When all may not be as it seems
  16. Mandatory reporting
  17. Vertebral artery dissection in hypertensive disorders of pregnancy: a case series and literature review
  18. Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod
  19. Justification for conducting neurological clinical trials as part of patient care within private practice
  20. Ibuprofen for the treatment of TTH
  21. Generic substitution in contravention of doctor's prescriptions
  22. Nontraumatic spinal cord ischaemic syndrome
  23. The Effect of Biofeedback as a Psychological Intervention in Multiple Sclerosis: A Randomized Controlled Study
  24. Author reply
  25. SUDEP revisited – A decade on: Have circumstances changed?
  26. Sudden unexpected death in epilepsy
  27. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
  28. Anti-synthetase syndrome associated with anti PL-12 and anti-Signal recognition particle antibodies and a necrotizing auto-immune myositis
  29. Importance of cardiological evaluation for first seizures
  30. The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy
  31. Mandatory notification of impaired doctors
  32. An appraisal of the new operational definition of epilepsy—Then and now
  33. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs)
  34. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
  35. Rectal carbamazepine as effective long-acting treatment after cluster seizures and status epilepticus
  36. Compulsive gambling possibly associated with antiepileptic medication
  37. Analysis of the latest Austroads guidelines for fitness to drive as promulgated in March 2012
  38. Prevalence of positive syphilis serology and meningovascular neurosyphilis in patients admitted with stroke and TIA from a culturally diverse population (2005–09)
  39. Rebound exacerbation multiple sclerosis following cessation of oral treatment
  40. Sleep-disordered breathing in multiple sclerosis
  41. Heat stroke induced cerebellar dysfunction: A “forgotten syndrome”
  42. Legal and Forensic Medicine
  43. Episodic Dyscontrol, Rage, and Violence
  44. Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
  45. Low positive predictive value of the ABCD2 score in emergency department transient ischaemic attack diagnoses: the South Western Sydney Transient Ischaemic Attack Study
  46. Membership survey of the Australasian College of Legal Medicine: Quality assurance
  47. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
  48. Changed constitution without change in brand name – The risk of generics in epilepsy
  49. Pharmaceutical excipients
  50. The neurological diagnostic consultation
  51. The neurological examination
  52. The neurological examination
  53. Vertigo
  54. The neurological examination
  55. Peripheral neuropathy
  56. Non-organic neurological diseases
  57. Dementia
  58. Epilepsy
  59. Headache
  60. The neurology of sleep
  61. Pain
  62. Preface
  63. Parkinson's disease
  64. Multiple sclerosis
  65. Muscles
  66. Stroke
  67. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome
  68. ‘Prolactinoma: are dopamine agonists still first choice?’
  69. Letters to the editor
  70. Epilepsy stigma: What do we know and where next?
  71. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
  72. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
  73. Levetiracetam in chronic daily headache: A double-blind, randomised placebo-controlled study
  74. Glyphosate–surfactant herbicide-induced reversible encephalopathy
  75. What is legal medicine – Are legal and forensic medicine the same?
  76. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
  77. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
  78. Epilepsy and the Law
  79. Validation of Emergency and Final Diagnosis Coding in Transient Ischemic Attack: South Western Sydney Transient Ischemic Attack Study
  80. Decreasing presentations of seizures to emergency departments in a large Australian population
  81. Strategies for developing sleep research
  82. Crossed cerebellar hyperperfusion on ictal FDG PET in astrocytoma
  83. Sleepiness in multiple sclerosis: A pilot study
  84. Value of therapeutic drug level monitoring and unbound (free) levels
  85. Epilepsy and law
  86. An alternative perspective on the management of status epilepticus
  87. Analysis – What is legal medicine?
  88. Medical aspects of fitness to drive. What do public hospital doctors know and think
  89. Meningococcal meningitis and a negative cerebrospinal fluid: Case report and its medicolegal implications
  90. Association between ulcerative colitis and multiple sclerosis
  91. The teaching of legal medicine in Australasia
  92. Road not taken: lessons to be learned from Queen v. Gillett
  93. Opinions, attitudes and practices of Australian neurologists with regard to epilepsy and driving
  94. The ethics of excluding women who become pregnant while participating in clinical trials of anti-epileptic medications
  95. Transfer of Lamolrigine Into Breast Milk
  96. SUDEP—to discuss or not discuss: that is the question
  97. Seizure control and treatment in pregnancy
  98. Analysis and overview of the guidelines for assessing fitness to drive for commercial and private vehicle drivers
  99. Efficacy and safety of levetiracetam 1000–3000mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study
  100. Clinical Trials and the Independence of Investigators
  101. Review of the legal obligations of the doctor to discuss Sudden Unexplained Death in Epilepsy (SUDEP)—a cohort controlled comparative cross-matched study in an outpatient epilepsy clinic
  102. A pilot study of compassionate use of Levetiracetam in patients with generalised epilepsy
  103. Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor
  104. Gabapentin in the prophylaxis of chronic daily headache
  105. Cervical ependymoma presenting with brainstem and cerebellar signs: case report
  106. The absorption of gabapentin following high dose escalation
  107. Legal aspects of epilepsy
  108. ILAE Commission on the Burden of Epilepsy, Subcommission on the Economic Burden of Epilepsy: Final Report 1998–2001
  109. Economics in Epilepsy Treatment Choices: Our Certain Fate?
  110. AUStralian Study of Titration to Effect Profile of Safety (AUS‐STEPS): High‐Dose Gabapentin (Neurontin) in Partial Seizures
  111. Pilot Study of Prevalence of Parkinson’s Disease in Australia
  112. Conduct of Trials in Private Clinical Practice
  113. Facial pain as a presenting feature of intracerebral haemorrhage
  114. Validating a screening questionnaire for parkinsonism in Australia
  115. Economic Analysis of Epilepsy Care
  116. Letters to the Editor
  117. The Burden of Epilepsy for the Patient: The Intangible Costs
  118. Vision for the Future
  119. Safety and efficacy of vigabatrin and carbamazepine in ne wly diagnosed epilepsy: a multicentre randomised double-blind study
  120. Interface of epilepsy and sleep disorders
  121. Confidentiality and the management of patients with epilepsy who fail to comply with doctor's advice not to drive: A survey of medical/legal opinions in Australia
  122. Double‐Blind, Placebo‐Controlled, Lamotrigine in Treatment‐Resistant Generalised Epilepsy
  123. Aggressive Behaviour in Intellectually Challenged Patients with Epilepsy Treated with Lamotrigine
  124. Final Report of the ILAE Commission on Economic Aspects of Epilepsy, 1994–1997
  125. The use of CPAP in patients with refractory epilepsy
  126. Professional privilege, driving and epilepsy, the doctor's responsibility
  127. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures
  128. An appraisal of the clinical use of lamotrigine under the special access scheme
  129. Report of the International League Against Epilepsy Commission on Economic Aspects of Epilepsy
  130. Melatonin Response in Active Epilepsy
  131. Management and Attitudes of Epilepsy by a Group of Sydney General Practitioners
  132. A simultaneous electrocardiogram is important when electroencephalography is used in the evaluation of loss of consciousness
  133. Clinical Trials of Antiepileptic Drugs Performed in the Private Practice Setting
  134. Automatisms—The Gulf Between Medicine and the Law
  135. Therapeutic recreation programmes for children with epilepsy
  136. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures.
  137. Cross‐Reactive Skin Eruption with Both Carbamazepine and Oxcarbazepine
  138. Chromosome fragility in the Lennox‐Gastaut epilepsy syndrome
  139. Brown‐Sequard Syndrome Following Chemotherapy and Radiotherapy in Breast Carcinoma—A Case Report
  140. Doctors’ perspectives regarding the changes in the delivery of health care to people with developmental disabilities
  141. The Role of Computed Tomography in the Assessment of Neurologic Sequelae of Decompression Sickness
  142. PLASMA CONCENTRATIONS OF UNBOUND VALPROATE IN THE MANAGEMENT OF EPILEPSY
  143. Psychosocial Sequelae of Epilepsy: The Role of Associated Cerebral Pathology
  144. An Accurate Assessment of the Prevalence Ratio of Epilepsy Adequately Adjusted by Influencing Factors
  145. False-Negative Response Rate in Epidemiologic Studies to Define Prevalence Ratios of Epilepsy
  146. A Survey of Doctors in Sydney, Australia: Perspectives and Practices Regarding Epilepsy and Those Affected by It
  147. Population Prevalence of Epilepsy in Sydney, Australia
  148. Dealing with epileptics
  149. Doctors' Perspectives of Epilepsy
  150. Myoclonus in Down's Syndrome
  151. Individualized Patient Assessment in the Treatment of Epilepsy with Sodium Valproate
  152. Rectal administration of sodium valproate in status epilepticus
  153. Pharmacokinetics of sodium valproate in epileptic patients: Prediction of maintenance dosage by single-dose study